Trending...
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Martial Artists Invited to Push Their Limits at the 2025 JMAC Crucible in Ann Arbor
Non-invasive therapy for non-melanoma skin cancer is now available at select GenesisCare treatment sites
MUNICH & SYDNEY - Michimich -- OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies. And GenesisCare, the largest provider of cancer care in Australia, the UK and Spain are excited to announce a partnership to provide an innovative, non-invasive, single-session treatment for non-melanoma skin cancer. OncoBeta and GenesisCare have recently completed recruitment of a phase 4 clinical trial and are now expanding access to suitable skin cancer patients.
Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.
Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, OncoBeta Group CEO, stated "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."
More on Michimich.com
"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia" said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia".
GenesisCare Chief Medical Officer, Dr Marie Burke, stated "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment".
Always talk to your doctor about what treatment options are suitable for you.
Healthcare Professionals can contact GenesisCare or OncoBeta for more information.
About GenesisCare
GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.
GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.
More on Michimich.com
Every year, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain. Headquartered in Sydney, Australia, the organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the U.S.
For more information visit www.genesiscare.com/au
About OncoBeta® GmbH
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.
Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, OncoBeta Group CEO, stated "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."
More on Michimich.com
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Rocket Companies to Announce Second Quarter 2025 Results on July 31, 2025
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia" said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia".
GenesisCare Chief Medical Officer, Dr Marie Burke, stated "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment".
Always talk to your doctor about what treatment options are suitable for you.
Healthcare Professionals can contact GenesisCare or OncoBeta for more information.
About GenesisCare
GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.
GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.
More on Michimich.com
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- Unlocking PLM's Full Potential: CIMdata Reveals the Executive Support Imperative in Free Webinar
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
Every year, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain. Headquartered in Sydney, Australia, the organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the U.S.
For more information visit www.genesiscare.com/au
About OncoBeta® GmbH
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Source: OncoBeta GmbH
0 Comments
Latest on Michimich.com
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- RECOMMENDED CASH AND SHARE COMBINATION OF DOWLAIS GROUP PLC WITH AMERICAN AXLE & MANUFACTURING HOLDINGS, INC.
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- Roofman USA Shares the Pros and Cons of Summer vs. Fall Roof Replacements
- Wilderness Construction Shares Storage Solutions to Take You Kitchen Remodel to the Next Level
- The Bridge Chiropractic in Ann Arbor Offers Groundbreaking Approach to Knee Pain Relief
- Martial Artists Invited to Push Their Limits at the 2025 JMAC Crucible in Ann Arbor
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Michigan Personal Injury Lawyers, Matz Injury Law, Announces Over $10 Million Savings for Clients Through Reduced Fee Model
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands